We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-6.51%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.59B
AUM Growth
-$241M
Cap. Flow
-$119M
Cap. Flow %
-7.49%
Top 10 Hldgs %
53.34%
Holding
89
New
20
Increased
22
Reduced
13
Closed
28

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$50.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$41.3M
3
LOW icon
Lowe's Companies
LOW
+$36.2M
4
UTHR icon
United Therapeutics
UTHR
+$30.3M
5
RH icon
RH
RH
+$23.1M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$40.8M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$37.9M
3
AZO icon
AutoZone
AZO
+$28.7M
4
BIIB icon
Biogen
BIIB
+$28.2M
5
PLYA
Playa Hotels & Resorts
PLYA
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 31.87%
2 Consumer Discretionary 15.3%
3 Industrials 5.59%
4 Consumer Staples 4.92%
5 Technology 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLLI icon
76
Ollie's Bargain Outlet
OLLI
$4.31B
– –
-80,000
Closed -$6.83M
OVID icon
77
Ovid Therapeutics
OVID
$427M
– –
-1,780,000
Closed -$3.15M
PCRX icon
78
Pacira BioSciences
PCRX
$1.04B
– –
-1,072,000
Closed -$40.8M
PLYA
79
DELISTED
Playa Hotels & Resorts
PLYA
– –
-3,580,000
Closed -$27.3M
PTCT icon
80
PTC Therapeutics
PTCT
$6.18B
– –
-400,000
Closed -$15.1M
SJM icon
81
CALL
J.M. Smucker
SJM
$13.5B
– –
-200,000
Closed -$23.3M
TSN icon
82
Tyson Foods
TSN
$21.5B
– –
-52,000
Closed -$3.61M
PETQ
83
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
– –
-158,000
Closed -$4.96M
SPPI
84
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-1,928,000
Closed -$20.6M
CLVS
85
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-2,100,000
Closed -$37.9M
SRRA
86
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-39,000
Closed -$2.67M
FPRX
87
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-300,000
Closed -$4.02M
MNK
88
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-1,500,000
Closed -$21.7M
ACHN
89
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-2,500,000
Closed -$7.4M
1 2 3
4

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Armistice Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Armistice Capital held 89 positions worth $1.59B, down 13% from $1.83B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Armistice Capital withdrew a net $119M in Q2 2019, closing 28 positions and reducing 13 holdings. Its most notable exit was Pacira BioSciences, an estimated $40.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Armistice Capital opened a new position in Vanda Pharmaceuticals worth $44.5M.

  • Armistice Capital's largest Q2 2019 buy was Vanda Pharmaceuticals: 3,158,000 shares worth $44.5M.
  • Armistice Capital added most to Edgewell Personal Care in Q2 2019, an estimated $20.3M increase.
  • Armistice Capital's biggest Q2 2019 reduction was Biogen, cutting an estimated $28.2M.
  • Armistice Capital fully exited Pacira BioSciences in Q2 2019, selling an estimated $40.8M.
  • Armistice Capital's ten largest holdings make up 53% of its $1.59B portfolio in Q2 2019.
  • Armistice Capital opened 20 new positions and closed 28 in Q2 2019.
  • Armistice Capital's portfolio value fell 13% quarter-over-quarter to $1.59B.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.